NATICK, Mass., Aug. 14 -- Boston Scientific Corporation (NYSE: BSX - News) today announced the launch of its next generation intravascular ultrasound (IVUS) imaging system, the Galaxy®2 System. It is now available in the United States and Canada. It is scheduled to be available in Europe and Japan later this year.
Imaging systems consist of consoles and catheters, which together provide cross-sectional and longitudinal ultrasound images of the inside of an artery or the heart. IVUS technology is used in the diagnosis and management of coronary and peripheral vascular disease, as well as to visualize intracardiac structures during electrophysiology procedures. Boston Scientific is the worldwide market leader in IVUS technology.
"The new Galaxy2 System demonstrates our commitment to provide the latest advancements in IVUS technology," said Paul LaViolette, Senior Vice President and Group President, Cardiovascular. "It offers a number of new features that allow more sophisticated imaging, providing valuable information in this new drug-eluting stent era."
"Galaxy is state-of-the-art technology," said Gary Mintz, M.D., of the Cardiovascular Research Foundation in New York. "It provides unprecedented flexibility and image quality for IVUS procedures."
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices. The Company's products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks inherent in commercialization of emerging technologies, physician acceptance of new products, competitive offerings and other factors described in the Company's filings with the Securities and Exchange Commission.
| Contacts |
|
Milan Kofol (508-650-8569)
Investor Relations
Boston Scientific Corporation |
Paul Donovan (508-650-8541)
Media Relations
Boston Scientific Corporation
|
|